Geiparvarin
Geiparvarin is an anticancer agent and an inhibitor of MAO-B (pIC50 = 6.84 μM). Geiparvarin exerts anti-tumor effects by downregulating COX2 expression and inhibiting angiogenesis. Geiparvarin blocks the cell cycle at the G1 phase and induces apoptosis of cancer cells. Geiparvarin has anti-microtubule activity and destroys the cytoskeleton to exert anti-proliferative effects. Geiparvarin has research significance for lung cancer, leukemia, and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 36413-91-9
- Formule: C19H18O5
- Masse moléculaire:326.34
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
IC50 & Target
|
COX-2 |
Caspase 3 |
MAO-B 6.84 μM (pIC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
18.02 μM
Compound: Geiparvarin
|
Cytotoxicity against human A549 cells by after 48 hrs by MTT assay
Cytotoxicity against human A549 cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
| FM3A | IC50 |
7.87 μg/mL
Compound: 1 (geiparvarin)
|
Inhibitory effect on the proliferation of murine mammary carcinoma FM3A cells
Inhibitory effect on the proliferation of murine mammary carcinoma FM3A cells
|
[PMID: 1588564] |
| HeLa | IC50 |
9.09 μM
Compound: Geiparvarin
|
Cytotoxicity against human HeLa cells by after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
| L02 | IC50 |
>300 μM
Compound: Geiparvarin
|
Cytotoxicity against human L02 cells by after 48 hrs by MTT assay
Cytotoxicity against human L02 cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
| L1210 | IC50 |
5.31 μg/mL
Compound: 1 (geiparvarin)
|
Inhibitory effect on the proliferation of murine leukemia L1210 cells.
Inhibitory effect on the proliferation of murine leukemia L1210 cells.
|
[PMID: 1588564] |
| MDA-MB-231 | IC50 |
9.88 μM
Compound: Geiparvarin
|
Cytotoxicity against human MDA-MB-231 cells by after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
| MT4 | IC50 |
1.64 μg/mL
Compound: 1 (geiparvarin)
|
Inhibitory effect on the proliferation of human T-lymphocyte MT-4 cells.
Inhibitory effect on the proliferation of human T-lymphocyte MT-4 cells.
|
[PMID: 1588564] |
| Raji | IC50 |
8.25 μg/mL
Compound: 1 (geiparvarin)
|
Inhibitory effect on the proliferation of human B-lymphoblast Raji cells.
Inhibitory effect on the proliferation of human B-lymphoblast Raji cells.
|
[PMID: 1588564] |
| SGC-7901 | IC50 |
7.59 μM
Compound: Geiparvarin
|
Cytotoxicity against human SGC7901 cells by after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
| SW480 | IC50 |
20.34 μM
Compound: Geiparvarin
|
Cytotoxicity against human SW480 cells by after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells by after 48 hrs by MTT assay
|
[PMID: 22579780] |
In Vitro
Geiparvarin (Compound 8) (72h) inhibits the proliferation of human tumor cell lines (IC50: 5.7 μM for SHSY5Y, 6.3 μM for HL-60, 9.2 μM for K562, 9.8 μM for HT-1080, 11.5 μM for A-549)[1].
Geiparvarin (8 μM, 24-72 h) arrests HL-60 cell cycle at the G1 phase and induces caspase-independent apoptosis[1].
Geiparvarin (72 h) shows complete inhibitory effects on drug-resistant cell lines and is not affected by transporters that mediate the efflux of antitumor drugs[1].
Geiparvarin (1 μM, 24 h) inhibits cell invasion ability in HOS and 143B cells[2].
Geiparvarin (0.5-2 μM, 24-48 h) activates apoptotic pathways in HOS and 143B cells, inhibits COX2 and downstream angiogenic pathways, and induces caspase-dependent apoptosis[2].
Geiparvarin exerts its antitumor effects in osteosarcoma cells by downregulating COX2, and overexpression of COX2 reverses its inhibition of proliferation and invasion[2].
Geiparvarin (10 μM, 24 h) disrupts the cytoskeleton, especially intermediate filaments, in Balb/c 3T3 fibroblasts[3].
Geiparvarin (0.01-10 μM) shows a significant increase in the inhibition rate of MAO-B extracted from rat liver mitochondria with increasing concentration, pIC50 = 6.84 (IC50 = 1.45 μM)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 cells, HL-60 cells, HT-1080 cells, A-549 cells, SHSY5Y cells , CEM cells, CEM/Vbl100 cells, LoVo cells, LoVo/Doxo cells;
-
Concentration:
-
Incubation Time:72 h
-
Result:Had an IC50 range of 5.7 μM-11.5 μM in human tumor cell lines.
-
Cell Line:L02 cells, A-549 cells, HeLa cells, QGY-7701 cells, SW480 cells , SGC7901 cells, MDA-MB-231 cells
-
Concentration:
-
Incubation Time:48 h
-
Result:Had significant inhibitory activity against a variety of cancer cells (such as SGC7901: IC₅₀=7.59 μM; HeLa: IC₅₀=9.09 μM) and had low toxicity to normal liver cells L02 (IC₅₀>300 μM).
Ranged in IC₅₀ values of cells after treatment: 7.59-20.34 μM.
-
Cell Line:HOS Cells, 143B Cells, HL-60 cells
-
Concentration:0.5 μM, 1 μM, 2 μM for HOS Cells and 143B Cells 8 μM for HL-60 cells
-
Incubation Time:24 h, 48 h for HOS Cells and 143B Cells; 72 h for HL-60 cells
-
Result:Significantly increased Caspase-3 enzyme activity.
Reduced the proportion of G1 phase cells from 43.7 % to S phase cells from 34.8 % after 72 hours.
Induced DNA fragmentation in HL-60 cells.
Caused chromatin condensation and apoptotic body formation in HL-60 cells, as observed by electron microscopy.
-
Cell Line:HOS Cells, 143B Cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Significantly reduced the number of cells penetrating the membrane.
-
Cell Line:HOS Cells, 143B Cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:24 h, 48 h
-
Result:Down-regulated COX2, VEGF, CD31 (angiogenesis-related proteins) and up-regulated cleaved PARP/caspase-3 (apoptosis proteins).
-
Cell Line:Balb/c 3T3 fibroblasts
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Slightly shortened microfilaments and reduced their density, inhibited microtubule polymerization, and caused the intermediate filament vimentin to reorganize into short fibers and accumulate around the nucleus.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:143B/9901 cells xenograft tumor model in female nude mice (6 weeks)[2]
-
Dosage:0.5 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every 3 days for several weeks; Intraperitoneal injection (i.p.),every day (for safety assessment)
-
Result:Significantly reduced the tumor volume and weight of the subcutaneous transplanted tumor model, and increased the apoptotic cells in the tumor tissue.
Inhibited the growth of primary tumors and lung metastasis, and reduced the number and size of lung metastatic nodules.
Increased the weight of mice, and there was no pathological damage to major organs.
Chemical Information
-
CAS No. 36413-91-9
-
Masse moléculaire 326.34
-
Formule C19H18O5
-
SMILES
C/C(C(OC(C)1C)=CC1=O)=C\COC2=CC=C(C=CC(O3)=O)C3=C2
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Phalloidin F-actin cytoskeleton staining
Phalloidin F-actin staining detects polymerized filamentous actin in fixed and permeabilized specimens by using fluorescent phalloidin or phalloidin-derived phallotoxins that bind actin filaments and generate a fluorescence microscopy readout corresponding to F-actin organization, including stress fibers, cortical actin, filament bundles, and tissue-specific actin networks. Phalloidin stabilizes F-actin by reducing actin subunit dissociation from filament ends, and fluorescent phallotoxins were established as tools for visualizing actin-containing structures in eukaryotic cells.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Pureté et documentation
Références
[1]. Giampietro Viola, et al. Synthesis, cytotoxicity, and apoptosis induction in human tumor cells by geiparvarin analogues. Chem Biodivers. 2004 Sep;1(9):1265-80. [Content Brief]
[2]. Bin Wang, et al. Geiparvarin Inhibits the Progression of Osteosarcoma by Down-regulating COX2 Expression. Chem Biodivers. 2004 Sep;1(9):1265-80. [Content Brief]
[3]. C Bocca, et al. Cytoskeleton-interacting activity of geiparvarin, diethylstilbestrol and conjugates. Chem Biol Interact. 2001 Sep 28;137(3):285-305. [Content Brief]
[4]. Angelo Carotti, et al. Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies. Bioorg Med Chem Lett. 2002 Dec 16;12(24):3551-5. [Content Brief]
[5]. Yikai Zhang, et al. Convenient synthesis of novel geiparvarin analogs with potential anti-cancer activity via click chemistry. Eur J Med Chem. 2012 Jul:53:356-63. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)